
Computed tomographic assessment of autologous fat injection augmentation for vocal fold paralysis
Author(s) -
Nishio Naoki,
Fujimoto Yasushi,
Hiramatsu Mariko,
Maruo Takashi,
Suga Kenji,
Tsuzuki Hidenori,
Mukoyama Nobuaki,
Shimono Mariko,
Toriyama Kazuhiro,
Takanari Keisuke,
Kamei Yuzuru,
Sone Michihiko
Publication year - 2017
Publication title -
laryngoscope investigative otolaryngology
Language(s) - English
Resource type - Journals
ISSN - 2378-8038
DOI - 10.1002/lio2.125
Subject(s) - medicine , paralysis , nuclear medicine , computed tomographic , subcutaneous fat , vocal fold paralysis , surgery , laryngeal paralysis , computed tomography , adipose tissue
Objective To perform a quantitative computed tomography (CT) assessment of short‐ and long‐term outcomes of autologous fat injection augmentation in patients with unilateral vocal fold paralysis. Study Design Retrospective case series. Methods Twelve patients who had undergone autologous fat injection augmentation for unilateral vocal fold paralysis in our hospital between 2011 and 2015 were enrolled in this study. The autologous fat for injection was acquired from periumbilical subcutaneous tissue and was injected orally using a special‐purpose laryngeal injection needle. To evaluate the injected fat at the follow‐up assessments, CT was performed at several times after surgery in clinical practice. All thin‐section CT images were transferred to a workstation, and the volume of the injected fat was calculated. Results Patients comprised 6 men and 6 women with a mean age at the time of surgery of 62.9 years (range, 46–82 years). The actual injected fat volume was 1.1–2.5 ml (mean, 1.6 ml). In seven patients assessed by CT two days after surgery, the average residual rate of the injected fat was 63.9%. The mean residual rates of the injected fat were 30.0% at 3 months, 33.7% at 6 months, 29.2% at 12 months, and 32.0% at 24 months. Conclusions Although the injected fat volume decreased within the first three months and the residual rate of the injected fat was 30.0% at three months after injection, the residual fat volume remained at the same level for 24 months after injection. Level of Evidence 4